AstraZeneca Unloads Three Asthma and Rhinitis Drugs to Covis Pharma for $350 Million

As AstraZeneca focuses on its strategy of divesting assets and spending on its own pipeline, the company sold rights to three older drugs to Covis Pharma for $350 million.